Figure 5

Low expression of BACH1 plus wild-type p53 correlate with better prognosis in GBM patients receiving TMZ therapy.

(A,B) Kaplan–Meier curves showing the overall survival of GBM patients with high or low expression of BACH1 & TP53-wt(A) or TP53-mut(B) in 90 GBM patients receiving TMZ therapy using the TCGA database. (C) the hotspot mutation sites of TP53 in GBM. L: Leucine; P: Proline; T: Threonine; N: Asparagine; R: Arginine; H: Histidine; G: Glycine; Y: Tyrosine; C: Cystine; S: Serine; W: Tryptophan; D: Asparticacid. (D) DBTRG-05MG cells were separately transfected with FLAG-p53-WT or FLAG-p53-mutants. Co-IP assays were performed using anti-IgG or anti-FLAG antibody. (E) The RNA level of MGMT in DBTRG-05MG cells transfected with FLAG-p53-WT or FLAG-p53-mutants. Student’s t-tests were performed. Data are presented as mean ± SEM (**P < 0.01).